Gain Therapeutics Announces Completion of Target Enrollment in Phase 1b Clinical Study Evaluating GT-02287 in People With Parkinson's Disease With or Without a GBA1 Mutation

Stock Information for Gain Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Gain Therapeutics Inc.

Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2025
Gain Therapeutics Reports Financial Results for Third Quarter 2025 and Provides Corporate Update
Gain Therapeutics to Present at Neuroscience 2025
Gain Therapeutics to Attend the 2025 Maxim Growth Summit
Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson's Disease
Gain Therapeutics Presents Initial Data from Phase 1b Clinical Study of GT-02287 in Parkinson's Patients at International Congress of Parkinson's Disease and Movement Disorders® 
Gain Therapeutics to Participate at Drug Discovery Innovation Programme 2025
Gain Therapeutics Begins Its GT-02287 Phase 1b Extension Study in People with Parkinson's Disease

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.